ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 742,10
0,11%
Dow Jones
43 487,83
0,00%
DAX
20 974,30
-0,15%
Brent Oil
78,385
-1,05%
Bitcoin
104 324,50
2,25%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Cingulate Inc (CING) Cours

Cingulate Inc

Cingulate Inc (CING)

NASDAQ
4,76
-0,22
(-4,42%)
Fermé 18 Janvier 10:00PM
Retardé de 15 minutes
4,76
0,00
( 0,00% )
Avant marché: 1:35PM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
4,76
Prix Achat
4,70
Prix Vente
4,99
Volume échangé
106
0,00 Fourchette du Jour 0,00
1,8001 Plage de 52 semaines 58,32
Cap du marché
15,29M
Clôture Veille
4,76
Ouverture
-
Dernière Transaction
1
@
4.7
Dernière heure de transaction
13:34:55
Volume financier
-
VWAP
-
Volume moyen (3 m)
176 118
Actions en circulation
3 212 233
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,65
Bénéfice par action (BPA)
-7,33
Chiffre d'affairess
-
Bénéfice net
-23,54M

À propos de Cingulate Inc

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions cha... Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.cingulate.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Cingulate Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CING. Le dernier cours de clôture d'Cingulate était de US$4,76. Au cours de la dernière année, les actions de Cingulate ont été négociées dans une fourchette de prix de US$ 1,8001 à US$ 58,32.

Cingulate compte actuellement 3 212 233 actions en circulation. La capitalisation boursière d'Cingulate est de US$15,29 million. Cingulate a un ratio cours/bénéfice (ratio PE) de -0.65.

CING Dernières nouvelles

Plus de nouvelles

Final Study Completed for Cingulate’s Lead Asset CTx-1301

No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

07 Janvier 2025
GlobeNewswire Inc.

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

23 Décembre 2024
GlobeNewswire Inc.

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

07 Novembre 2024
GlobeNewswire Inc.

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...

08 Octobre 2024
GlobeNewswire Inc.

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

12 Septembre 2024
GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]

03 Septembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

03 Septembre 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

31 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

29 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

28 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.12.145922746784.665.164.61070934.82470472CS
4-0.04-0.8333333333334.85.5884.27012400184.77330358CS
120.439.930715935334.335.5883.021761184.34747387CS
260.780819.62203457983.979220.831.8001208822910.51379832CS
52-51.16-91.487839771155.9258.321.8001124793310.70704247CS
156-571.24-99.1736111111576595.1761.800168736785.68474009CS
260-1195.24-99.6033333333120012361.8001689316110.44205039CS

CING - Frequently Asked Questions (FAQ)

What is the current Cingulate share price?
The current share price of Cingulate is US$ 4,76
How many Cingulate shares are in issue?
Cingulate has 3 212 233 shares in issue
What is the market cap of Cingulate?
The market capitalisation of Cingulate is USD 15,29M
What is the 1 year trading range for Cingulate share price?
Cingulate has traded in the range of US$ 1,8001 to US$ 58,32 during the past year
What is the PE ratio of Cingulate?
The price to earnings ratio of Cingulate is -0,65
What is the reporting currency for Cingulate?
Cingulate reports financial results in USD
What is the latest annual profit for Cingulate?
The latest annual profit of Cingulate is USD -23,54M
What is the registered address of Cingulate?
The registered address for Cingulate is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Cingulate website address?
The website address for Cingulate is www.cingulate.com
Which industry sector does Cingulate operate in?
Cingulate operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ASSTAsset Entities Inc
US$ 0,9747
(109,84%)
36,7M
BBGIBeasley Broadcast Group Inc
US$ 13,17
(59,25%)
24
EDRYEuroDry Ltd
US$ 18,08
(58,88%)
12
LXEOLexeo Therapeutics Inc
US$ 7,99
(57,59%)
1
HSDTHelius Medical Technologies Inc
US$ 1,17
(55,79%)
18,62M
GOEVCanoo Inc
US$ 0,46
(-65,93%)
2,04M
ELVNEnliven Therapeutics Inc
US$ 10,11
(-52,91%)
20
CUBLionheart Holdings
US$ 5,11
(-49,51%)
1
ALRSAlerus Financial Corporation
US$ 12,01
(-38,79%)
13
MDXGMiMedx Group Inc
US$ 6,01
(-34,10%)
9
CRKNCrown Electrokinetics Corporation
US$ 0,1391
(11,28%)
82,15M
ASSTAsset Entities Inc
US$ 0,9747
(109,84%)
36,7M
NIVFNewGenIvf Group Ltd
US$ 0,3631
(4,04%)
21,35M
HSDTHelius Medical Technologies Inc
US$ 1,17
(55,79%)
18,62M
CGBSCrown LNG Holdings Ltd
US$ 0,8269
(10,58%)
12,86M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CING
Cingulate
BIT
UC9154
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés